Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
5 Z+ A8 R3 o8 D3 o# V& u q4 fNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 1 T& g; b; W# A& @. C2 e$ R
+ Author Affiliations
5 L. [4 }* f6 P! V
3 L: L, F+ Z6 Y" X, Z5 K. N/ L' ?1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan , j, c3 h. g8 B" u) f
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
4 C% y% u- C$ K/ \% N3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
0 |% N: @' I/ U- j* o# c3 d4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan + h+ b# W4 ]# h) d' r$ @0 d- H
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
. a! }" G Y9 l$ R- l/ o( l* \6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
% }2 t& E# L! _! |7Kinki University School of Medicine, Osaka 589-8511, Japan ) i, B: j! |8 |" t' T
8Izumi Municipal Hospital, Osaka 594-0071, Japan
. ^( k1 G8 O3 n4 C2 d# T* L5 Q9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
8 I. R8 l0 r( OCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp ! @) Z- T/ |' J# X) F Y/ N
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
, }, {* _2 Y3 r+ a2 l
5 B* D8 b$ k" x' v7 I* a! C- R9 [ |